Compound library / Research / Investigational

VIP (Vasoactive Intestinal Peptide)

Naturally occurring neuropeptide explored off-label (often as a nasal spray) for inflammation and biotoxin/mold-illness protocols popularized outside mainstream medicine.

CategoryResearch / Investigational
Regulatory standingNo approved product cited
Typical routeNasal
Half-life~1-2 minutes
Common dose range50 mcg per spray, several times/day per common protocols
Typical cycle lengthWeeks to months in published off-label protocols

BioHack Track models VIP (Vasoactive Intestinal Peptide) at a half-life of 0.02 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Typically supplied as a compounded pre-mixed nasal spray.

Storage

Refrigerate or freeze per compounding pharmacy instructions.

Cautions

Compounded, not FDA-approved as a standalone product; evidence for mold/CIRS protocols is largely anecdotal.

Track VIP (Vasoactive Intestinal Peptide) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Research / Investigational

Look up the research

These open a search of each database for VIP (Vasoactive Intestinal Peptide) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support